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Abstract A global, open-label, expanded-access trial (EAT)
provided sunitinib treatment on a compassionate-use basis to
patients withmetastatic renal cell carcinoma (mRCC) between
2005 and 2011. This retrospective analysis examines out-
comes in patients from Central and East European (CEE)
countries participating in the global EAT. Sunitinib (starting
dose 50 mg orally once daily, with dose reduction for toxicity)
was administered in repeated 6-week cycles (4 weeks on and
2 weeks off) until occurrence of disease progression or unac-
ceptable toxicity. Tumor assessments were guided by Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) criteria
but were performed according to local standards of care. In
total, 401 CEE patients received sunitinib (median treatment
duration 9.6 months), of whom 378 were evaluable for tumor
response. The most frequent grade ≥3 toxicities were fatigue
(7.5 %), hypertension (7.0 %), thrombocytopenia (6.5 %),
diarrhea (4.2 %), nausea and hand-foot syndrome (both
3.7 %) and neutropenia (3.0 %). Median overall survival
was 30.7 months (95 % CI 23.3, months). Overall survival
tended to be longer in cytokine-naïve than cytokine-
experienced patients (median 60.8 vs. 27.5 months; P=
0.1324). Among patients with evaluable tumors, 4.0 %
achieved a complete and 14.6 % a partial response [objective
response rate (ORR) 18.5 % (95 % CI 14.7, 22.8 %)]. Median
progression-free survival was 11.6 months (95 % CI 10.3,
12.8 months). Sunitinib demonstrates safety and effectiveness
in real-world mRCC patients in CEE countries. Expanded-
access program patients showed a lower tumor response rate
but similar survival outcomes to patients in the pivotal Phase
III clinical trial of sunitinib in mRCC.
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Introduction
Sunitinib, an orally active, small-molecule inhibitor that tar-
gets multiple receptor tyrosine kinases involved in tumor
growth and angiogenesis, including vascular endothelial
growth factor receptor (VEGFR)-1, -2- and -3, platelet-
derived growth factor receptor (PDGFR)-α and -β, stem cell
growth factor receptor (c-KIT), fms-like tyrosine kinase 3
(FLT3), colony-stimulating factor 1 receptor (CSF-1R), and
glial cell line-derived neurotrophic factor receptor (RET) [1].
Sunitinib was approved in Europe in 2006 for the treatment of
metastatic renal cell carcinoma (RCC) and has since become a
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reference standard of care for first-line treatment of favorable-
or intermediate-risk metastatic RCC and as a second-line
option in poor-risk disease [2, 3]. The drug’s efficacy was
demonstrated in a large international randomized Phase III
registration trial that compared sunitinib with interferon-α in
treatment-naïve patients with metastatic RCC (n=750) [4, 5].
Sunitinib demonstrated superiority over interferon-α in terms
of progression-free survival (PFS) (median 11 vs. 5 months;
P<0.001), overall survival (OS) (median 26.4 vs.
21.8 months; P=0.05) and objective response rate (47 vs.
12 %; P<0.001) [4, 5].
Community-based patients with advanced RCC typically
present with more diverse demographic and disease charac-
teristics than the patients selected for inclusion in clinical
trials. Expanded-access programs generally apply less strin-
gent entry criteria than clinical trials, and allow patients who
have no access to, or who are ineligible for clinical trials, the
opportunity to receive a new drug therapy prior to its approval.
The findings from expanded-access programs complement
those of regular clinical trials by providing insight into real-
world treatment patterns, safety and effectiveness in a broad
spectrum of community-based cancer patients, including
those with poor prognosis.
A global, open-label, expanded-access trial was initiated at
sites in North, Central and South America, Europe, Asia-
Pacific, Australia and Africa in 2005 to provide sunitinib on
a compassionate-use basis to patients with metastatic RCC in
countries where regulatory approval had not yet been granted
[6]. Final results based on extended patient follow-up over the
period 2005–2011 confirmed the safety and effectiveness of
sunitinib in community-based metastatic RCC patients across
52 countries with different practice patterns [7]. The drug’s
toxicity profile in this real-world population was consistent
with that demonstrated in the pivotal Phase III trial [4, 5].
Median PFS and OS were 9.4 months and 18.7 months,
respectively, and the objective response rate was 16 % [7].
This retrospective analysis of the sunitinib global
expanded-access trial data examines treatment outcomes
among study participants in Central and Eastern Europe, a
region with some of the highest rates of RCC in the world [8],
as well as historically inferior oncological outcomes and lim-
ited second- and third-line treatment options compared with
other parts of Europe [9–11].
Patients and Methods
Patient Selection and Study Treatment
Patient Selection
Patient eligibility criteria for inclusion in the global expanded-
access trial were minimized to achieve a diverse study
population. Patients were required to be ≥18 years of age, to
have histologically confirmed metastatic RCC (any histolog-
ical subtype), adequate organ function, and no major comor-
bidities, and to have recovered from any prior treatment
toxicities. Study entry was permitted regardless of Eastern
Cooperative Oncology Group (ECOG) performance status
and treatment status (treatment-naïve or -experienced), and
patients with asymptomatic brain metastases were also eligi-
ble for study entry. Patients were excluded if they had received
prior sunitinib treatment.
Study approval was obtained from the institutional review
board or independent ethics committees at each participating
centre. All patients provided their written informed consent.
The study was conducted in accordance with the International
Conference on Harmonisation Good Clinical Practice guide-
lines. The study was supported by Pfizer Inc. and registered
with the ClinicalTrials.gov registry (NCT00130897).
For the Central and East European (CEE) sub-analysis,
patients with metastatic RCC who received sunitinib treat-
ment at study sites in Bulgaria, Croatia, the Czech Republic,
Hungary, Romania, the Russian Federation, Serbia, Slovakia
and Slovenia were selected from the global expanded-access
trial population.
Study Treatment
Patients received oral sunitinib at an initial dose of 50mg once
daily (reduced to 37.5, 25 or, in some cases, 12.5 mg once
daily in the event of toxicity) in repeated 6-week cycles of
4 weeks on followed by two weeks off treatment, until disease
progression, unacceptable toxicity or consent withdrawal.
Palliative radiotherapy (other than to target lesions) was per-
mitted at the discretion of the treating physician; in such cases,
sunitinib treatment was briefly interrupted for each session of
radiotherapy.
Study Assessments
Safety assessments (physical examination and clinical labora-
tory tests) were performed at screening and on Days 1, 14 and
28 of treatment cycle 1, and on Days 1 and 28 of each
subsequent cycle. Adverse events were graded for severity
according to the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE), version
3.0 and were assessed for relationship to sunitinib treatment.
Patients who discontinued sunitinib therapy because of an
adverse event were followed-up until resolution or stabiliza-
tion of symptoms.
Tumor assessments were guided by Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.0, but were not
scheduled in the study protocol. These were performed in
accordance with the local standard pattern of care at each
participating site, and there was no coordinated (central)
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review of CT scans. Outcomes of interest were objective
response rate (complete+partial responses), PFS (time from
start of sunitinib treatment to disease progression or death
from any cause) and OS (time from start of sunitinib treatment
to death from any cause, with censoring at last follow-up for
surviving patients).
Statistical Analysis
Safety and efficacy analyses were conducted in the intent-to-
treat (ITT) population, comprising all patients who received at
least one dose of sunitinib. Subjects with non-RECIST tumor
measurements or other data integrity issues were excluded
from those efficacy analyses based on tumor response. Medi-
an PFS and OS were estimated using the Kaplan-Meier meth-
od. Intergroup comparisons of survival functions were con-
ducted for different prognostic factors [prior cytokine therapy,
and Memorial Sloan-Kettering Cancer Center (MSKCC) risk
category] using the log-rank test at a two-sided significance
level of 0.05. Hazard ratios and corresponding 95% two-sided
confidence intervals (CIs) for the intergroup comparisons
were calculated from Cox proportional hazard models consid-
ering the different prognostic factors. Objective response rates
and corresponding 95 % two-sided CIs were calculated using
standardmethods based on binomial distribution. All P-values
are considered exploratory.
Results
Patient Population
In total, 4543 patients in the global expanded-access trial
received one or more doses of sunitinib (ITT population), of
whom 401 patients (8.8 %) were from the identified CEE
countries, including Bulgaria (n=18), Croatia (n=71), Czech
Republic (n=50), Hungary (n=59), Romania (n=52), the
Russian Federation (n=58), Serbia (n=31), Slovakia (n=41)
and Slovenia (n=21).
The CEE patient population had a generally favorable
prognosis, with 85 % of patients having an ECOG per-
formance status of 0 (35.4 %) or 1 (49.9 %), and 87 %
of patients being classified at intermediate (45.9 %) or
favorable (40.6 %) risk according to the MSKCC risk
criteria. The great majority of patients (93 %) had clear-
cell histology and had undergone prior nephrectomy;
almost two-thirds of patients had received prior systemic
cytokine therapy, but few (3 %) had received anti-
angiogenic therapy (Table 1). At screening, the main
sites of metastasis were the lungs (71.1 % of patients),
bone (31.2 %) and liver (20.2 %); approximately 50 %
of patients showed lymph node involvement.
Treatment Exposure
The CEE sub-population received a median of 7 (range 1–57)
cycles of sunitinib treatment, amounting to a median duration
of treatment of 9.6 months (95 % CI 8.1, 11.1 months)
(Table 2). The median duration of patient follow-up (from
commencement of sunitinib therapy until censorship for sur-
vival or death) was 15.5 (range 0.2–75.0) months. Following
initiation of sunitinib treatment (starting dose 50 mg once
daily), dose reduction was required in 159 (39.6 %) patients;
dose was decreased to 37.5 mg (32.2 % of patients), 25 mg
(7.2 %) or 12.5 mg (0.2 %). The study was discontinued by
388 (96.8 %) patients, with the most common reasons for
discontinuation being lack of treatment efficacy (43.1 %),
Table 1 Patient demographics and baseline clinical characteristics
Characteristic Intent-to-treat population (n=401)
Median age, years (range) 58.0
(19 79)
Age ≥65 years, n (%) 89 (22.2 %)
Male/Female, n (%) 298/103 (74.3/25.7 %)
ECOG Performance status,n (%)
0 142 (35.4 %)
1 200 (49.9 %)
2 48 (11.9 %)
3 4 4 (1.0 %)
Missing data 7 (1.7 %)
Histology, n (%)
Clear cell 373 (93.0 %)
Non-clear cell 28 (7.0 %)
Total number of metastatic sites, n (%)
0 4 (1.0 %)
1 111 (27.7 %)
2 133 (33.2 %)
3 73 (18.2 %)
>3 80 (20.0 %)
Prior cancer surgery, n (%)
Prior nephrectomy 374 (93.0 %)
Prior radiotherapy 123 (30.7 %)
Prior systemic therapy
Chemotherapy 155 (38.7 %)
Anti-angiogenic 12 (3.0 %)
Immunotherapy 247 (61.6 %)
Modified MSKCC risk group, n (%)
Favorable 163 (40.6 %)
Intermediate 184 (45.9 %)
Poor 37 (9.2 %)
Missing 17 (4.2 %)
ECOG=Eastern cooperative oncology group; MSKCC=Memorial
sloan-kettering cancer center
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death (15.0 %), poor treatment tolerability (11.5 %) and with-
drawal of consent (10.0 %).
Safety
The most frequently reported treatment-related adverse
events in the ITT population (n=401) were diarrhea
(31.9 %), nausea (30.9 %), fatigue (29.4 %), stomatitis
(27.7 %), decreased appetite (23.7 %) and hypertension
(23.2 %), which were predominantly of low-grade sever-
ity. The most common grade≥3 adverse events were
fatigue (7.5 %), hypertension (7.0 %), thrombocytopenia
(6.5 %), diarrhea (4.2 %), nausea (3.7 %), hand-foot
syndrome (3.7 %) and neutropenia (3.0 %). Treatment-
related adverse events occurring in≥5 % of the CEE
patient population are listed in Table 3.
Efficacy
In total, 378 patients were evaluable for tumor response,
of whom 15 (4.0 %) achieved a complete response and
55 (14.6 %) a partial response, translating into an objec-
tive response rate of 18.5 % (95 % CI 14.7, 22.8 %). In
total, 204 patients (54.0 %) exhibited stable disease,
including 12 patients (3.2 %) who had stabilization for
<3 months and 192 patients (50.8 %) for ≥3 months, and
41 patients (10.8 %) showed disease progression
(Table 4).
Median PFS in the population evaluable for tumor
response (n=378) was 11.6 months (95 % CI 10.3,
12.8 months) (Fig. 1a). PFS was longer in cytokine-naïve
patients (n=161) (median 12.2 months, 95 % CI 9.3,
16.5 months) than in cytokine-experienced patients (n=
217) (median 11.0 months, 95 % CI 8.8, 12.6 months).
Intergroup comparison indicated a significant inferiority
in PFS for cytokine-experienced compared with cyto-
kine-naïve patients (hazard ratio 1.376, 95 % CI 1.065,
1.779; P=0.0141).
Median overall survival in the ITT population (n=401) was
30.7 months (95 % CI 23.3, – months) (Fig. 1b). Overall
survival was a function of MSKCC risk, and was of longer
duration in patients with good prognosis (median overall
survival was not reached) than in those with intermediate
prognosis (median 23.1 months, 95 % CI 18.9, 33.8 months)
or poor prognosis (median 6.4 months, 95 % CI 3.9,
8.0 months) (Fig. 2). Overall survival tended to be shorter in
cytokine-experienced patients (median 27.5 months, 95 % CI
20.9, 36.6 months) than in cytokine-naïve patients (median
60.8months, 95%CI 26.3, –months), although the difference
did not reach statistical significance (hazard ratio 1.276, 95 %
CI 0.928, 1.754; P=0.1324) (Fig. 3).
Table 2 Treatment and disposition of the patient population
Characteristic Intent-to-treat population
(n=401)
Sunitinib therapy
Median number of treatment cycles
(range)
7 (1 57)
Dose reduction, n (%) 159 (39.6 %)
Discontinuation, n (%) 388 (96.8 %)
Primary reason for discontinuation, n (%)
Lack of efficacy 173 (43.1 %)
Death 60 (15.0 %)
Adverse events 46 (11.5 %)
Consent withdrawn 40 (10.0 %)
Lost to follow-up 17 (4.2 %)
Other (e.g., sponsor decision) 52 (12.9 %)
Table 3 Safety profile of sunitinib: treatment-related adverse events
occurring in ≥5 % of patients
Adverse event Intent-to-treat population (n=401) n (%)
All grades Grade ≥3
Diarrhea 128 (31.9 %) 17 (4.2 %)
Nausea 124 (30.9 %) 15 (3.7 %)
Fatigue 118 (29.4 %) 30 (7.5 %)
Stomatitis 111 (27.7 %) 9 (2.2 %)
Decreased appetite 95 (23.7 %) 8 (2.0 %)
Hypertension 93 (23.2 %) 28 (7.0 %)
Dysgeusia 76 (19.0 %) 1 (0.2 %)
Vomiting 71 (17.7 %) 10 (2.5 %)
Thrombocytopenia 63 (15.7 %) 26 (6.5 %)
Dyspepsia 63 (15.7 %) 0
Hand-foot syndrome 62 (15.5 %) 15 (3.7 %)
Rash 58 (14.5 %) 6 (1.5 %)
Anemia 56 (14.0 %) 10 (2.5 %)
Leukopenia 53 (13.2 %) 8 (2.0 %)
Asthenia 53 (13.2 %) 11 (2.7 %)
Dermatitis 51 (12.7 %) 11 (2.7 %)
Yellow skin 42 (10.5 %) 1 (0.2 %)
Neutropenia 38 (9.5 %) 12 (3.0 %)
Hair colour changes 35 (8.7 %) 2 (0.5 %)
Epistaxis 34 (8.5 %) 0
Skin discoloration 29 (7.2 %) 0
Mucosal inflammation 27 (6.7 %) 2 (0.5 %)
Skin exfoliation 27 (6.7 %) 0
Extremity pain 23 (5.7 %) 2 (0.5 %)
Headache 22 (5.5 %) 1 (0.2 %)
Glossitis 21 (5.2 %) 1 (0.2 %)
Blood creatinine increased 21 (5.2 %) 0
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Discussion
The results of this retrospective analysis of the global
expanded-access trial dataset testify to the safety and effec-
tiveness of sunitinib in real-world patients receiving treatment
for metastatic RCC in Central and Eastern Europe. Survival
outcomes in the CEE sub-population closely mirrored those of
the overall (global) patient population of the expanded-access
trial [7], and in several respects compared favorably with
those obtained in the pivotal Phase III randomized clinical
trial of sunitinib in metastatic RCC [4, 5]. Thus, while the
sunitinib treatment arm in the clinical trial showed median
PFS and overall survival durations of 11.0 and 26.4 months,
respectively [4, 5], the real-world CEE population had median
PFS and overall survival times of 11.6 and 30.7 months.
However, the objective tumor response rate in the real-world
CEE population (18.5 %) was considerably lower than that
reported in the sunitinib treatment arm of the clinical trial
(47 %) [4, 5]. This discrepancy is likely due to the fact that,
in contrast to the clinical trial protocol, tumor assessments in
the expanded-access study were performed on an irregular
basis, and in a non-standardized manner across the participat-
ing study centers. As a result, estimates of tumor response
obtained in the expanded-access study are subject to greater
a
b
Fig. 1 Kaplan-Meier estimate of
(a) progression-free survival in
the tumor-evaluable population
receiving sunitinib (n=378), and
(b) overall survival in the intent-
to-treat population receiving su-
nitinib (n=401)
Table 4 Efficacy of sunitinib therapy in the intent-to-treat population
Outcome Intent-to-treat population (n=401)
Survival
Median OS, months 30.7
95 % CI (23.3, )
Median PFS†, months 11.6
95 % CI (10.3, 12.8)
Antitumor responsea
Objective response, (CR+PR), n (%) 70 (18.5 %)
[95 % CI] [14.7 %, 22.8 %]
Complete response, n (%) 15 (4.0 %)
Partial response, n (%) 55 (14.6 %)
Stable disease ≥3 months, n (%) 192 (50.8 %)
Stable disease <3 months, n (%) 12 (3.2 %)
Progressive disease, n (%) 41 (10.8 %)
Not assessed/evaluable 16 (4.3 %)
Missing data 47 (12.4 %)
CI=Confidence interval, CR=Complete response, OS=Overall survival,
PFS=Progression-free survival, PR=Partial response
a PFS and anti-tumor response were assessed in 378 evaluable patients
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variation and greater potential inaccuracy than is the case in
the controlled clinical trial setting. Moreover, the overall
prognosis of patients in an expanded-access program is likely
to be inferior to that of patients enrolled into a Phase III
clinical trial.
The duration of sunitinib treatment in the CEE population
was somewhat shorter than in the Phase III trial population
(median 9.6 vs. 11.0 months) - presumably because the
expanded-access trial was initiated at a time (2005) when
experience in the use of anti-angiogenic therapy was limited
and the investigators received no formal guidance on the
preferred length of treatment. Nevertheless, comparison of
outcomes between the two populations is justified by their
generally similar demographic and clinical features: the suni-
tinib treatment arm in the pivotal Phase III study, although
treatment-naïve and restricted to patients with an ECOG per-
formance status of 0-1 (and consequently having a better
prognosis), resembled the CEE population in terms of age,
gender balance, prior nephrectomy, sites of metastasis and
MSKCC risk profile.
Despite the clinical diversity of patients in the CEE popu-
lation, the toxicity profile of sunitinib in this group [predom-
inantly diarrhea (31.9 %), nausea (30.9 %), fatigue (29.4 %),
stomatitis (27.7 %), decreased appetite (23.7 %) and
hypertension (23.2 %)] was broadly consistent with that in
the more homogenous clinical trial population, for whom the
most frequently reported treatment-related adverse events
were diarrhea (61 %), fatigue (54 %), nausea (52 %),
dysgeusia (46 %) and anorexia (34 %). Similarly, the pattern
of grade ≥3 adverse events was compatible between the CEE
population [most commonly fatigue (7.5 %), hypertension
(7.0 %), thrombocytopenia (6.5 %), diarrhea (4.2 %), nausea
(3.7%), hand-foot syndrome (3.7%) and neutropenia (3.0%)]
and the clinical trial population [most commonly hypertension
(12 %), fatigue (11 %), diarrhea (9 %), hand-foot syndrome
(9 %), asthenia (7 %), nausea (5 %) and vomiting (4 %)]. The
generally lower incidence of adverse events in the CEE pop-
ulation may be due to the nature of expanded-access
programmes, with their primary purpose being to provide
treatment to broad patient populations. Despite observance
of the standardized safety monitoring and reporting require-
ments specified in the study protocol, adverse events may
have been under-reported.
Information to date on real-world (i.e., non-clinical trial)
treatment patterns and clinical outcomes with sunitinib in
advanced and metastatic RCC has come largely from retro-
spective observational studies typically involving small pa-
tient samples; these have included studies conducted in Spain
Fig. 2 Kaplan-Meier estimates of overall survival byMSKCC risk group
(intent-to-treat population). Inter-cohort comparison of favorable versus
intermediate/poor risk: hazard ratio (favourable=1, intermediate/poor
=0)=0.428, 95 % CI=0.305, 0.600; P<0.0001. Inter-cohort comparison
of poor versus intermediate/favorable risk: hazard ratio (poor=1, inter-
mediate/favorable=0)=5.288, 95 % CI=3.385, 8.263; P<0.0001
Fig. 3 Kaplan-Meier estimates of
overall survival by prior cytokine
exposure (intent-to-treat
population). Inter-cohort compar-
ison of prior cytokine versus no
prior cytokine: hazard ratio (Yes=
1, No =0)=1.276, 95 % CI 0.928,
1.754; P=0.1324
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[12], Italy [13], the United Kingdom [14], the United States
[15–18] and South Korea [19]. Findings from such studies
have consistently indicated significant rates of treatment mod-
ification, including dose reduction, treatment interruption and
treatment discontinuation, often as the result of adverse events
associated with sunitinib therapy [12–20]. The global
expanded-access trial and the present CEE subanalysis sup-
plement these retrospective observational studies by providing
extended prospective follow-up data for large, ethnically and
clinically diverse populations of metastatic RCC patients re-
ceiving sunitinib therapy within different healthcare systems.
Among the CEE study population, approximately 40 % of
patients required reduction in sunitinib dose from the starting
level of 50 mg (typically to 37.5 mg), while poor treatment
tolerability was responsible for 11.5 % of patients
discontinuing sunitinib therapy.
Central and Eastern Europe have some of the highest rates
of RCC in the world, with the Czech Republic reporting
prevalences of kidney cancer of ~20 per 100,000 in men and
~10 per 100,000 in women [8]. Possible contributory factors
include high levels of industrial pollution, occupational expo-
sure to chemical carcinogens, employment in the agricultural
sector, high tobacco use, obesity and low dietary intake of fruit
and vegetables [21–23]. Cancer outcomes in Central and
Eastern Europe have historically been inferior to those in
Western Europe [9–11], and the continent is still divided by
differences in cancer mortality. While overall cancer deaths
have been steadily decreasing in Western Europe since the
1990s, the cancer mortality rate in Central and Eastern Europe
has continued to increase [24, 25], and is predicted to reach
201 per 100,000 (men) and 106 per 100,000 (women) by 2015
[26]. Several factors may play a part in the geographical
variation of cancer incidence and mortality, including differ-
ences in prevalence of underlying risk factors (including local
and regional environmental factors), differences in host sus-
ceptibility, and/or regional variations in cancer detection and
prevention campaigns, reporting, classification systems and,
importantly, available treatment options [27]. The relative
contributions that these factors make to the overall picture is
not known, but differences in cancer care may account for a
substantial proportion of the higher cancer mortality rates seen
in some countries. The findings of the present study suggest
that, with access to appropriate therapeutic options, clinical
prospects for patients with metastatic RCC patients in Central
and Eastern Europe are as good as those in Western Europe
and North America.
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